Moneycontrol PRO
The Learning Curve
The Learning Curve
HomeNewsBusinessMoneycontrol ResearchAstral Poly Q4: Premium play on the CPVC volume growth and high margin adhesive business

Astral Poly Q4: Premium play on the CPVC volume growth and high margin adhesive business

While medium term tailwinds with regard to demand for CPVC pipes backed by capacity expansion and cost savings from backward integration remains, elevated valuation (53x 2019e earnings) and the intensified competition in the piping industry keeps on the sidelines at current price levels.

May 25, 2018 / 15:18 IST
Supreme Industries Ltd. | In FY21 so far, the stock has gained 132 percent to Rs 2018 on February 24 from 869 on March 31, 2021.
MC Technical rating as on February 25shows that on Daily: Very Bullish, Weekly: Very Bullish and, Monthly: Very Bullish. (for more detail click here)

Supreme Industries Ltd. | In FY21 so far, the stock has gained 132 percent to Rs 2018 on February 24 from 869 on March 31, 2021. MC Technical rating as on February 25shows that on Daily: Very Bullish, Weekly: Very Bullish and, Monthly: Very Bullish. (for more detail click here)

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Anubhav Sahu
Moneycontrol Research

Astral Poly Technik reported yet another robust quarterly performance, driven by volume growth in pipes business and improved margins across divisions. Operational improvement in the adhesives business and the steady progress in capacity addition projects were the key positives.

The company’s foray into new categories and the project execution capabilities are commendable, but the stock price is factoring in the medium term growth prospects, in our view.

Volume-led growthCapture3
Source: Company

Astral Poly’s standalone March quarter net sales rose 7 percent year-on-year, mainly due to a 10 percent YoY increase in volume sales. EBITDA margins improved 142 bps to 17.7 percent, compared to the management guidance of 14-15 percent.

Lower raw material costs helped, and the margin would have been even better, but for the increase in other expenses. Quarter-on-quarter as well, raw material as percentage of net sales have fallen to 58 percent from 67 percent.

In the adhesives business, overall margin is improving. Quarterly EBITDA margin stood at 20.5 percent (vs. 15.2 percent in Q4 FY17) helped by mainly aided by Resinova operations and economies of scale at its new facilities at Kanpur (UP) and Santej (Gujarat)

International operations (SEAL IT) reported a 15 percent sales growth YoY with the induction of new machinery at its US plants. The US operations are expected to export high margin adhesives products to both UK and India in the current year. While EBITDA margins are still in the high single digits, export of high margin adhesives products are expected to push EBITDA margins towards company’s guidance of double digit margins in FY19.

Capacity expansion projects are on track
In the current quarter, the company has started trial production at Ghiloth Plant (Rajasthan) which has an installed capacity of 22,700 tons. Here, commercial production will start in July.

Further, construction work for expansion at Hosur facility (15,000 tons) is nearing completion and should start production in September. Together, these projects should help increase company’s installed capacity to about 1,75,000 tons. That is a 27 percent increase compared to the installed capacity in FY17.

Additionally, company’s adhesive business, Resinova Chemie has launched new products, one of them being Cyanoacrylate under the brand name “Resiquick”.

Current fiscal year to witness volume and margin expansion
FY19 is expected to witness a volume growth of about 15 percent backed by both capacity expansion and better capacity utilization. Further, higher contribution from both Resonova and SEAL IT divisions is expected to aid margins. Along with this company benefits from backward integration in the pipes business.

Capture2
Source: Moneycontrol Research

On the positive sides, Astral will gain from tailwinds like demand for CPVC pipes backed by capacity expansion and cost savings from backward integration. But the stock is expensive at 53 times 2019 estimated earnings, and the industry suffers from stiff competition. Long term investors can consider accumulating this stock on declines.

For more research articles, visit our Moneycontrol Research page

Anubhav Sahu is Principal Research Analyst, Moneycontrol Research. He has been writing research/recommendation pieces on Chemicals and Pharma sectors along with Equity strategy themes. He has previously worked with Credit Suisse and BNP Paribas.
first published: May 25, 2018 03:18 pm

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347